Clinical trials: PsA (Psoriatic Arthritis)
Rheumatoid Arthritis, Psoriatic Arthritis
A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
The purpose of the study is to assess systemic certolizumab pegol (CZP) exposure, the formation of anti-CZP antibodies and safety of CZP across the course of pregnancy in study participants with chronic inflammatory diseases.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Axial Spondyloarthritis
- Trial name
- CHERISH (NCT04163016)
- Testing
- Pharmacokinetics of certolizumab pegol
- Where
- 9 sites in United States, France and 4 more
- Volunteers
- 22 people
- Sponsor
- UCB Biopharma SRL
Psoriatic Arthritis
A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis
This is a study to assess the long-term safety and tolerability of bimekizumab in subjects with psoriatic arthritis
- Trial name
- BE ACTIVE 2 (NCT03347110)
- Testing
- Bimekizumab
- Where
- 37 sites in United States, Czechia and 4 more
- Volunteers
- 184 people
- Sponsor
- UCB Biopharma SRL
Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.
Ankylosing spondylitis, radiographically negative axial spondyloarthritis, psoriatic arthritis, polymyalgia rheumatica, Takayasu arteritis, giant cell arteritis, non-ocular Behcet's disease, and enthesitis-related arthritis are…
- Conditions
- Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Nr-axSpA, Polymyalgia Rheumatica (PMR)
- Trial name
- V-MIRACLE (NCT06766552)
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Psoriatic Arthritis
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)
The purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab in participants with Active Psoriatic Arthritis (PsA).
- Trial name
- NCT02319759
- Testing
- Guselkumab, Ustekinumab
- Where
- 41 sites in United States, Canada and 5 more
- Volunteers
- 149 people
- Sponsor
- Janssen Research & Development, LLC
Psoriatic Arthritis
Changes in Body Composition Under Ustekinumab in PsA
There is not much body composition and bone mineral density data available for patients with psoriatic arthritis (rheumatoid arthritis) compared to control subjects.
- Trial name
- STELARA-CC (NCT03823924)
- Testing
- Bone mineral density (BMD)
- Where
- France
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Arthritis, Psoriatic
PsA Treatment With hOKT3γ1 (Ala-Ala)
hOKT3gamma1 (Ala-Ala) is a man-made antibody that is commonly used to prevent organ rejection. The purpose of this study is to determine whether hOKT3gamma1 (Ala-Ala) is safe and effective in psoriatic arthritis patients who are…
- Trial name
- PART (NCT00239720)
- Testing
- hOKT3gamma1(Ala-Ala)
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rheumatoid Arthritis, Psoriatic Arthritis
Prospective Analysis of Blood Flow Restriction Training in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Compared to Conventional Strength Training
This single-centre, randomized prospective interventional study assesses the effect of blood flow restriction training in patients with rheumatoid arthritis compared with conventional resistance training.
- Trial name
- BFR-RA/PSA (NCT07772687)
- Testing
- Blood Flow Restriction Training (BFRT), Conventional Strength Training
- Where
- Germany
- Volunteers
- 102 people
- Sponsor
- University of Bonn
Psoriasis (PsO), Psoriatic Arthritis (PsA)
Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab Environment
This was a retrospective observational study that relied on data extracted from patient chart review at the participating sites.
- Trial name
- NCT06666114
- Where
- Brazil
- Volunteers
- 232 people
- Sponsor
- Novartis Pharmaceuticals
PsA Patients Fulfilling CASPAR Criteria in Remission
Disparity Between Ultrasound- and Clinical Findings in Psoriatic Arthritis in Remission
Comparison of the proportion of Psoriatic arthritis patients in ultrasound remission (i.e. no power Doppler synovitis, tenosynovitis, dactylitis, enthesitis, PD=0) depending on whether patient and physician's global assessment of…
- Trial name
- PARURE (NCT03396679)
- Testing
- Ultrasound examination
- Where
- France
- Volunteers
- 62 people
- Sponsor
- University Hospital, Montpellier
PsA (Psoriatic Arthritis)
A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis
This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with active psoriatic arthritis. A total of 222 subjects are planned to be included.
- Trial name
- D2570-204 (NCT07315061)
- Testing
- D-2570
- Where
- China
- Volunteers
- 222 people
- Sponsor
- InventisBio Co., Ltd
Arthritis, Psoriatic
A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting
The purpose of this study is to assess how well guselkumab works in improving symptoms of psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red…
- Trial name
- GURU (NCT07220824)
- Where
- 21 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Janssen Research & Development, LLC
Psoriatic Arthritis
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an…
- Trial name
- EVOLUTION (NCT05669833)
- Testing
- Guselkumab, Golimumab
- Where
- 14 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of Pennsylvania
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
COMFI - a COMbined Fatigue Intervention
Background: Inflammatory arthritis (IA) encompasses autoimmune rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
- Conditions
- Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Spondyloarthritis (SpA), Inflammatory Arthritis
- Trial name
- COMFI (NCT06666452)
- Testing
- COMFI - a COMbined Fatigue Intervention
- Where
- 2 sites in Denmark, Sweden
- Volunteers
- 39 people
- Sponsor
- The Danish Center for Expertise in Rheumatology
Juvenile Idiopahtic Arthritis
Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
This is a 8-year extension study in pediatric subjects who have been diagnosed with one of 3 subtypes of Juvenile Idiopathic Arthritis (JIA) [extended oligoarticular JIA, enthestitis related arthritis (ERA), or psoriatic…
- Trial name
- CLIPPER2 (NCT01421069)
- Testing
- etanercept
- Where
- 35 sites in Australia, Belgium and 17 more
- Volunteers
- 109 people
- Sponsor
- Pfizer
Psoriatic Arthritis
A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).
- Trial name
- NCT07871721
- Testing
- Zasocitinib
- Volunteers
- 644 people
- Sponsor
- Takeda
Psoriatic Arthritis
Clinical and Molecular Characterization of Axial Psoriatic Arthritis (PsA), A Pilot Study
Objectives: To identify a candidate set of biomarkers specific to AxPsA. Overview: Clinical and imaging characterization of PsA patients will be combined with extensive molecular assessment of both liquid and tissue compartments…
- Trial name
- MONOLITH (NCT05925842)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
Psoriatic Arthritis
AsseSSing Impact in pSoriatic Treatment
Psoriatic arthritis (PsA) is a form of inflammatory arthritis associated with the skin condition psoriasis. A variety of different treatments are used to try to control arthritis and skin psoriasis and management often involves…
- Trial name
- ASSIST (NCT05171270)
- Testing
- Questionnaire
- Where
- 21 sites in France, Germany and 3 more
- Volunteers
- 503 people
- Sponsor
- University of Oxford
Psoriatic Arthritis (PsA)
Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
The purpose of this research study is to determine the effectiveness of adding deucravacitinib to the participant's current Psoriatic Arthritis (PsA) treatment to see if it improves their symptoms and quality of life.
- Trial name
- COMBo (NCT07280702)
- Testing
- Deucravacitinib
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- University of Texas Southwestern Medical Center
Rheumatoid Arthritis (RA, Psoriatic Arthritis (PsA
Efficacy Of Upadacitinib In Psoriatic Arthritis And Comparison To Rheumatoid Arthritis.
The general objective of the OPTIMA study is to assess the time course and interrelationship of imaging (ultrasound and magnetic resonance imaging), clinical, laboratory, and Patient Reported Outcome variables in patients with…
- Trial name
- OPTIMA (NCT06630715)
- Testing
- Upadacitinib 15 MG [Rinvoq]
- Where
- 14 sites in Italy
- Volunteers
- 178 people
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Psoriatic Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
This study includes two periods. The main objective of Period 1 is to compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo and versus adalimumab (Humira®) in participants with moderately to…
- Trial name
- SELECT - PsA 1 (NCT03104400)
- Testing
- Adalimumab, Upadacitinib
- Where
- 345 sites in United States, Argentina and 44 more
- Volunteers
- 1,705 people
- Sponsor
- AbbVie